Riassunto: La Commissione europea approva DAYBU® (trofinetide) come primo e unico trattamento dei sintomi neuro-comportamentali della sindrome di Rett nell'Unione Europea
Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Acadia Pharmaceuticals has received European Commission approval for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome. This approval applies to patients aged five and older, marking a significant advancement in care for this condition. The approval is a major milestone for the company and those affected by Rett syndrome.
Price reaction · baseline $29.35 (2026-08-24T14:28:00.000Z) · hit during market hours · clean, no other ACAD news in the window
day 0 close · peak
+1%
Market Sentiment Analysis
POSITIVE FACTORS
DAYBU is the first and only approved treatment for Rett syndrome in the EU.
The approval is a significant milestone for Acadia Pharmaceuticals.
The treatment is available for both adult and pediatric patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
4.5%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) oggi ha annunciato che la Commissione europea (CE) ha rilasciato l'autorizzazione all'immissione sul mercato di DAYBU (trofinetide) per il trattamento dei sintomi neuro-comportamentali della sindrome di Rett in pazienti adulti e pediatrici di almeno cinque anni di età, rendendo il farmaco il primo e unico trattamento approvato per la sindrome di Rett nell'Unione Europea (UE). “L'approvazione di DAYBU segna una tappa importan
Frequently Asked Questions
What is DAYBU approved for?
DAYBU is approved for treating neurobehavioral symptoms of Rett syndrome.
Who can use DAYBU?
DAYBU is approved for patients aged five years and older.
What significance does DAYBU's approval have?
It is the first and only treatment approved for Rett syndrome in the EU.
Which organization approved DAYBU?
The European Commission approved DAYBU for market authorization.